13
ALL13
Xilio TherapeuticsYear
13
ALL2
20253
20242
20231
20223
20212
2020DEALS // DEV.
13
ALL4
Deals9
DevelopmentsCountry
13
ALL13
U.S.A13
ALL1
AbbVie Inc1
Gilead Sciences9
Inapplicable1
Rock Springs Capital1
Takeda VenturesTherapeutic Area
13
ALL13
OncologyStudy Phase
13
ALL7
Phase I/ Phase II2
Phase I3
Preclinical1
Discovery PlatformDeal Type
13
ALL1
Collaboration9
Inapplicable1
Licensing Agreement1
Series B Financing1
Series C FinancingProduct Type
13
ALL6
Antibody2
Other Large Molecule5
ProteinDosage Form
13
ALL2
Intravenous2
Intravenous Infusion9
UndisclosedLead Product
13
ALL3
Atezolizumab1
Pembrolizumab1
Undisclosed1
Vilastobart2
XTX2013
XTX2022
XTX301Target
13
ALL5
CTLA-42
IL-12 receptor2
IL-2 receptor3
Tumor selective IL-21
UndisclosedLead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $2,152.0 million
Deal Type : Collaboration
AbbVie, Xilio Partner to Develop Tumor-Activated Immunotherapies
Details : The collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $52.0 million
February 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $2,152.0 million
Deal Type : Collaboration
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xilio Therapeutics Announces Phase 2 Data for Vilastobart in Colorectal Cancer
Details : XTX101 (vilastobart) is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.
Product Name : XTX101
Product Type : Antibody
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xilio Reports Phase 1 Safety Data for XTX301, Validating Tumor-Activated Therapies
Details : XTX301 is an investigational tumor-activated IL-12 designed to potently stimulate anti-tumor immunity. It is under phase 1 clinical development for the treatment of advanced solid tumor.
Product Name : XTX301
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xilio Therapeutics Announces Vilastobart Data in Advanced Solid Tumors
Details : XTX101 is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.
Product Name : XTX101
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Details : Gilead has an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12, currently in Phase I trials for neoplasms treatment.
Product Name : XTX301
Product Type : Other Large Molecule
Upfront Cash : $43.5 million
March 28, 2024
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XTX101 is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.
Product Name : XTX101
Product Type : Antibody
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Vilastobart,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vilastobart,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XTX101 is an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME).
Product Name : XTX101
Product Type : Antibody
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Vilastobart,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XTX202
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies, XTX202 exhibited tumor-selective biological activity and anti-tumor activity comparable to aldesleukin, a high-dose IL-2 therapy, at its maximum tolerated dose, while minimizing the severe toxicity observed with aldesleukin.
Product Name : XTX202
Product Type : Protein
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : XTX202
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vilastobart
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical studies of XTX101, its tumor-selective anti-CTLA-4 antibody, demonstrating combination potential with anti-PD-1 therapy, as well as enhanced preclinical activity and improved tolerability compared to ipilimumab.
Product Name : XTX101
Product Type : Antibody
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Vilastobart
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XTX202
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Clears Xilio Therapeutics’ IND Application for XTX202 to Treat Solid Tumors
Details : XTX202 is tumor-selective IL-2 product candidate, as a potential treatment for patients with solid tumors. XTX202 is designed to localize activity in the tumor microenvironment (TME).
Product Name : XTX202
Product Type : Protein
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : XTX202
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable